Lung Cancer
Feature
Popular Weight Loss Drugs Now for Patients With Cancer?
Research suggests that obesity can reduce the effectiveness of cancer therapies.
From the Journals
Minimal Risks With SBRT in Stage I NSCLC
Researchers explored toxicity and 90-day mortality outcomes in patients who received SBRT.
News from the FDA/CDC
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
The drug was approved for patients whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy...
From the Journals
Does Medicare Advantage Offer Higher-Value Chemotherapy?
Researchers conducted a cohort study to look at Medicare Advantage enrollment and treatment patterns for patients with cancer receiving...
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
News from the FDA/CDC
FDA Expands Indication for Amivantamab in Lung Cancer
The second-line approval for amivantamab plus chemotherapy ‘may address the most common mechanisms of treatment resistance to third-generation...
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
News from the FDA/CDC
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.
Conference Coverage
Osimertinib/Savolitinib Combo Shows Promise in NSCLC
Can combining two agents overcome MET-driven primary resistance in MET-aberrant, EGFR-mutated advanced NSCLC?
Conference Coverage
Ivonescimab: Possible New First-Line Standard in PD-L1–Positive Advanced NSCLC?
The results highlight ivonescimab’s potential to become a ‘new standard of care’ in advanced PD-L1–positive advanced NSCLC, according to an author...